Abbott trims 2026 profit forecast on Exact deal hit, shares fall

Estimated Price Impact
Pre vs Post NewsAI Executive Summary
Abbott Laboratories has revised down its profit forecast for 2026 following the announcement of a deal with Exact Sciences that will negatively impact its revenue. The company cited this deal as a primary reason for the adjustment, leading to a decline in its stock price. Investors reacted negatively, concerned about the implications for Abbott's future earnings. The revision highlights potential vulnerabilities in Abbott's product lineup. Market analysts suggest that this news could weigh on investor sentiment in the healthcare sector, particularly among diagnostics and lab equipment companies.
Trader Insight
"Traders should consider shorting Abbott's shares or looking for bearish options strategies, while monitoring for potential recovery signs in the healthcare sector."